NCT00626574View on ClinicalTrials.gov

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Subarachnoid Hemorrhage
Interventions
DRUG

Epoetin alfa

Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.

DRUG

Saline

3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.

Trial Locations (1)

33606

Tampa General Hospital, Tampa

Sponsors

Collaborators (1)

Ortho Biotech, Inc.
All Listed Sponsors
collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

University of South Florida

OTHER

NCT00626574 - Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa | Biotech Hunter | Biotech Hunter